Podcast Episode
Sevabertinib Approved for HER2-Mutant Nonsquamous NSCLC
About this episode
FDA accelerated approval makes sevabertinib available for previously treated advanced nonsquamous NSCLC with qualifying HER2 mutations, emphasizing precise molecular testing and avoiding broad HER2 eligibility.